Quick Answer
IOVANCE BIOTHERAPEUTICS, INC. reported Cash and Equivalents of $163.08 million for fiscal year 2025.
IOVANCE BIOTHERAPEUTICS, INC. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $163.08M | +41.0% |
| 2024 | $115.69M | +0.7% |
| 2023 | $114.89M | -50.4% |
| 2022 | $231.73M | +196.2% |
| 2021 | $78.23M | +16.2% |
| 2020 | $67.33M | +382.0% |
| 2019 | $13.97M | -83.0% |
| 2018 | $82.15M | -43.5% |
| 2017 | $145.37M | +36.2% |
| 2016 | $106.72M | +217.7% |
| 2015 | $33.59M | -25.2% |
| 2014 | $44.91M | +128.3% |
| 2013 | $19.67M | — |
| 2012 | $0.00 | -100.0% |
| 2011 | $510.2K | -60.5% |
| 2010 | $1.29M | +15553.0% |
| 2009 | $8.3K | +184.2% |
| 2008 | $2.9K | — |
| 2007 | $0.00 | — |
| 2007 | $0.00 | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $158.13M | -3.7% | +19.4% |
| June 30, 2025 | $132.47M | -42.1% | -22.8% |
| March 31, 2025 | $171.67M | +27.9% | +48.4% |
| December 31, 2024 | $115.69M | +0.7% | -29.5% |
| September 30, 2024 | $164.19M | -38.7% | -28.2% |
| June 30, 2024 | $228.68M | -0.6% | +70.4% |
| March 31, 2024 | $134.19M | -75.3% | +16.8% |
| December 31, 2023 | $114.89M | -50.4% | -57.1% |
- IOVANCE BIOTHERAPEUTICS, INC. showed an increase of +41.0% in Cash and Equivalents compared to the prior fiscal year.
- The most recent figure is from IOVANCE BIOTHERAPEUTICS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 24, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: